NOSTRIN

Across TCGA pan-cancer cohorts, NOSTRIN mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NOSTRIN data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NOSTRIN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NOSTRIN expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where NOSTRIN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.496	0.291	<.001	52	view →
CCRCC	OS	Tertile	All	0.930	0.527	.012	28	view →
LUAD	DFS	Median	II,III,IV	0.710	0.947	.004	6	view →
HNSC	DFS	Tertile	IV	0.800	0.440	.002	6	view →
LSCC	DFS	Tertile	All	0.898	1.000	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NOSTRIN–PDAC (DFS)

Open the PDAC breakdown →